Carol Wrzosek

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index380citations16works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(7), DNA Repair Mechanisms(6), Prostate Cancer Treatment and Research(4), Redox biology and oxidative stress(3), Glutathione Transferases and Polymorphisms(3)

Publications16 total

Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer
UNC Libraries·2021Open Access
Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer
UNC Libraries·2020Open Access
Serum‐free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models
The Prostate·2017· 16 citedOpen Access
Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer
Translational Oncology·2008· 24 citedOpen Access
A New Nonlinear Mixture Response Surface Paradigm for the Study of Synergism: A Three Drug Example
Current Drug Metabolism·2003· 47 cited
Chk1 signaling pathways that mediated G2M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350
Biochemical and Biophysical Research Communications·2002· 23 cited
Characterization of Protein Kinase chk1 Essential for the Cell Cycle Checkpoint after Exposure of Human Head and Neck Carcinoma A253 Cells to a Novel Topoisomerase I Inhibitor BNP1350
Molecular Pharmacology·2000· 24 cited
Characterization of Protein Kinase chk1 Essential for the Cell Cycle Checkpoint after Exposure of Human Head and Neck Carcinoma A253 Cells to a Novel Topoisomerase I Inhibitor BNP1350
Molecular Pharmacology·2000· 5 cited
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells
Cancer Chemotherapy and Pharmacology·2000· 25 cited
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications
European Journal of Cancer·1999· 13 cited
Cyclin E–Cdk2 Activation Is Associated with Cell Cycle Arrest and Inhibition of DNA Replication Induced by the Thymidylate Synthase Inhibitor Tomudex
Experimental Cell Research·1999· 29 cited
Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research·1998· 8 cited
DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
PubMed·1996· 56 cited
DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux
Cytometry·1996· 69 citedOpen Access
Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
PubMed·1994· 19 cited
Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment
Medical and Pediatric Oncology·1982· 22 citedOpen Access

Frequent Co-authors

Youcef M. Rustum(8), Ming-Biao Yin(5), Harry K. Slocum(5), Cheryl Frank(5), Hans Minderman(4), U. Vanhoefer(4), Bin Guo(4), James L. Mohler(4), Rami G. Azrak(3), Swaroop S. Singh(3), O. Harris Ford(3), Diana Mehedint(3), Mark Titus(3), Seiichi Matsui(2), Y M Rustum(2), Yun Li(2), Károly Tóth(1), Marthe Minderman(1), Marilyn L. Slovak(1), Mark A. Arredondo(1)